14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 CRNX stock ended at $47.20. This is 0.90% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.63% from a day low at $47.13 to a day high of $48.37.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Crinetics Pharmaceuticals Inc prices

Date Open High Low Close Volume
May 03, 2024 $47.52 $48.37 $47.13 $47.20 661 314
May 02, 2024 $45.61 $46.96 $44.84 $46.78 588 453
May 01, 2024 $43.82 $45.99 $43.66 $45.05 1 075 909
Apr 30, 2024 $43.16 $44.54 $43.16 $43.82 542 621
Apr 29, 2024 $42.47 $45.15 $41.59 $44.00 648 857
Apr 26, 2024 $42.49 $42.87 $41.67 $42.12 551 185
Apr 25, 2024 $42.44 $42.83 $41.05 $42.29 573 139
Apr 24, 2024 $45.02 $45.26 $43.28 $43.32 400 592
Apr 23, 2024 $43.57 $44.78 $42.05 $44.22 589 301
Apr 22, 2024 $43.53 $43.76 $42.71 $43.44 455 743
Apr 19, 2024 $42.36 $44.21 $42.20 $42.97 609 025
Apr 18, 2024 $44.05 $44.54 $42.87 $43.01 524 785
Apr 17, 2024 $43.73 $44.31 $43.28 $44.01 482 414
Apr 16, 2024 $42.88 $44.29 $42.63 $43.49 472 141
Apr 15, 2024 $44.49 $44.88 $43.44 $43.68 525 741
Apr 12, 2024 $47.75 $48.23 $43.71 $44.59 1 109 017
Apr 11, 2024 $46.54 $48.53 $46.20 $48.03 653 731
Apr 10, 2024 $45.22 $46.50 $45.17 $45.90 517 221
Apr 09, 2024 $46.39 $47.23 $46.09 $46.91 665 709
Apr 08, 2024 $47.81 $48.31 $45.75 $46.44 549 671
Apr 05, 2024 $46.39 $48.62 $45.52 $47.53 668 211
Apr 04, 2024 $48.50 $49.58 $46.00 $46.65 1 210 901
Apr 03, 2024 $45.57 $48.13 $44.91 $47.62 2 504 723
Apr 02, 2024 $45.87 $46.07 $44.43 $46.00 839 804
Apr 01, 2024 $46.65 $47.62 $44.52 $46.53 1 081 914
Click to get the best stock tips daily for free!

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c... CRNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT